Literature DB >> 15724144

The emerging role of the PI3-K-Akt pathway in prostate cancer progression.

L Li1, M M Ittmann, G Ayala, M-J Tsai, R J Amato, T M Wheeler, B J Miles, D Kadmon, T C Thompson.   

Abstract

The PI3-K-Akt pathway plays a central role in the development and progression of prostate cancer and other malignancies. We review original studies and summarize relevant sections of previous reviews concerning the relationships between abnormalities in the PI3-K-Akt pathway and prostate cancer progression. We discuss laboratory and clinical data that indicate gene perturbation and dysregulation of PI3-K-Akt pathway is common in prostate cancer and other malignancies. We further discuss the critical role of the PI3-K-Akt pathway in the oncogenic signaling network and provide examples that establish the PI3-K-Akt pathway as a focal point for the future development of informative biomarkers and effective therapies for prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15724144     DOI: 10.1038/sj.pcan.4500776

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  54 in total

1.  Isosilybin A induces apoptosis in human prostate cancer cells via targeting Akt, NF-κB, and androgen receptor signaling.

Authors:  Gagan Deep; Subhash C Gangar; Nicholas H Oberlies; David J Kroll; Rajesh Agarwal
Journal:  Mol Carcinog       Date:  2010-10       Impact factor: 4.784

2.  Overexpression of long non-coding RNA LOC400891 promotes tumor progression and poor prognosis in prostate cancer.

Authors:  Jun Wang; Gong Cheng; Xiao Li; Yongsheng Pan; Chao Qin; Haiwei Yang; Lixin Hua; Zengjun Wang
Journal:  Tumour Biol       Date:  2016-01-21

3.  Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells.

Authors:  Wen-Chin Huang; Xiangyan Li; Jian Liu; Jentai Lin; Leland W K Chung
Journal:  Mol Cancer Res       Date:  2011-11-07       Impact factor: 5.852

4.  Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth.

Authors:  Zhong Chen; Chunpeng Zhang; Dayong Wu; Hongyan Chen; Anna Rorick; Xiaoting Zhang; Qianben Wang
Journal:  EMBO J       Date:  2011-05-10       Impact factor: 11.598

5.  GGAP2/PIKE-a directly activates both the Akt and nuclear factor-kappaB pathways and promotes prostate cancer progression.

Authors:  Yi Cai; Jianghua Wang; Rile Li; Gustavo Ayala; Michael Ittmann; Mingyao Liu
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

6.  Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system.

Authors:  Yingyu Ma; Wei-Dong Yu; Alejandro A Hidalgo; Wei Luo; Remi Delansorne; Candace S Johnson; Donald L Trump
Journal:  Cell Cycle       Date:  2013-02-06       Impact factor: 4.534

7.  Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo.

Authors:  Marianne M Stanford; Mae Shaban; John W Barrett; Steven J Werden; Philippe-Alexandre Gilbert; Joe Bondy-Denomy; Lisa Mackenzie; Kevin C Graham; Ann F Chambers; Grant McFadden
Journal:  Mol Ther       Date:  2007-11-13       Impact factor: 11.454

8.  Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer.

Authors:  Akihiko Yoshizawa; Junya Fukuoka; Shigeki Shimizu; Konstantin Shilo; Teri J Franks; Stephen M Hewitt; Takeshi Fujii; Carlos Cordon-Cardo; Jin Jen; William D Travis
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

9.  NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma.

Authors:  Seong-Su Han; Hwakyung Yun; Dong-Ju Son; Van S Tompkins; Liangping Peng; Seung-Tae Chung; Joong-Su Kim; Eun-Sung Park; Siegfried Janz
Journal:  Mol Cancer       Date:  2010-04-30       Impact factor: 27.401

Review 10.  Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.

Authors:  Todd M Morgan; Theodore D Koreckij; Eva Corey
Journal:  Curr Cancer Drug Targets       Date:  2009-03       Impact factor: 3.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.